San Marcos, CA, United States of America

Berit Elissa Powers

USPTO Granted Patents = 2 

 

Average Co-Inventor Count = 1.3

ph-index = 1


Company Filing History:


Years Active: 2023

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Berit Elissa Powers: Innovator in Leukodystrophy Research

Introduction

Berit Elissa Powers is a prominent inventor based in San Marcos, CA (US). She has made significant contributions to the field of medical research, particularly in the area of leukodystrophies. With a total of 2 patents, her work focuses on developing compounds and methods to address critical health issues.

Latest Patents

Powers' latest patents include innovative approaches to modulating GFAP and PLP1. The first patent, "Compounds and methods for modulating GFAP," provides compounds, methods, and pharmaceutical compositions aimed at reducing the amount or activity of GFAP RNA in a cell or subject. This research is particularly relevant for ameliorating symptoms associated with leukodystrophies, such as Alexander Disease. The second patent, "Compounds and methods for modulating PLP1," similarly focuses on reducing the amount of proteolipid protein 1 in a cell or subject. This work addresses symptoms related to Pelizaeus-Merzbacher disease, including hypotonia, cognitive dysfunction, and respiratory distress.

Career Highlights

Berit Elissa Powers is currently employed at Ionis Pharmaceuticals, Inc., where she continues her groundbreaking research. Her work has the potential to significantly impact the treatment of various leukodystrophies, improving the quality of life for affected individuals.

Collaborations

Powers collaborates with esteemed colleagues, including Frank Rigo and Huynh-Hoa Bui, to advance her research and develop effective therapeutic solutions.

Conclusion

Berit Elissa Powers is a dedicated inventor whose work in leukodystrophy research is paving the way for innovative treatments. Her contributions to the field are invaluable and hold promise for many individuals facing these challenging conditions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…